FDA to Remove Breast Cancer Indication for Avastin Legal News Articles & Interviews

Washington, DC It's been expected—and today the manufacturer of Avastin begins a two-day appeal before the US Food and Drug Administration (FDA), pleading for more time in an attempt to save a controversial breast cancer drug.

Washington, DC The US. Food and Drug Administration has announced that the agency is recommending removing the breast cancer indication from the label for Avastin (bevacizumab) because the drug has not been shown to be safe and effective for that use.